Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment...
Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (OTCQB: TRUFF) (FSE: 4YX) ("Rhelion" or the "Company") is pleased to announce that it has completed its corporate...